One-month dual antiplatelet therapy after pci with resolute onyx des: final 2-year results from onyx one clear
J. Am. Coll. Cardiol
; 77(14 suppl. s): B14-B14, Apr., 2021. tab.
Artigo
em Inglês
| CONASS, Sec. Est. Saúde SP, SESSP-IDPCPROD, Sec. Est. Saúde SP
| ID: biblio-1343596
Biblioteca responsável:
BR79.1
ABSTRACT
BACKGROUND The optimal duration of dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI) varies based on ischemic and high bleeding risk (HBR) factors. METHODS Onyx ONE Clear was a prospective, global, multicenter study to assess the safety and effectiveness of 1-month DAPT in patients with HBR treated with Resolute Onyx zotarolimus-eluting stents (ZES). Patients with coronary artery disease and at least 1 HBR criterion were enrolled and prescribed DAPT for 1 month post-ZES implantation, followed by single antiplatelet therapy (SAPT) thereafter. The primary endpoint was composite of cardiac death or myocardial infarction (MI) from 1 month to 1 year. The current analysis presents final 2-year results from the study. RESULTS A total of 1,507 patients were analyzed at 2 years. Mean age was 74.0 9.5 years, 32.2% female, 38.8% with type 2 diabetes, 36.0% with previous revascularization, and 48.7% presented with an acute coronary syndrome. Patients were enrolled with mean 1.6 HBR criteria and 44.6% met 2 HBR criteria. Lesion characteristics included 50.0% moderate-to-severe calcification and 78.5% B2/C lesions. At 2 years, 81.1% of patients remained on SAPT, 5.6% received DAPT, and 12.5% were prescribed oral anticoagulation only. The composite of cardiac death or MI between 1 month and 2 years was 11.7%, with rates of 5.3% for cardiac death and 7.4% for MI. Most MIs were non-Q wave (6.7%). Rates of other secondary endpoints between 1 month and 2 years included 0.9% definite or probable stent thrombosis, 13.0% targetlesion failure, 4.7% clinically driven target-lesion revascularization, 2.6% stroke, and 6.2% Bleeding Academic Research Consortium (BARC) 3 to 5 bleeding events (Table 1). CONCLUSION Among patients with HBR treated with Resolute Onyx DES and SAPT after 1 month, 2-year ischemic event rates were acceptable despite an ongoing risk of major bleeding.
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Brasil
Base de dados:
CONASS
/
Sec. Est. Saúde SP
/
SESSP-IDPCPROD
Assunto principal:
Inibidores da Agregação Plaquetária
/
Intervenção Coronária Percutânea
Tipo de estudo:
Ensaio clínico controlado
Idioma:
Inglês
Revista:
J. Am. Coll. Cardiol
Ano de publicação:
2021
Tipo de documento:
Artigo
/
Congresso e conferência
Instituição/País de afiliação:
Cardiovascular Research Foundation/US
/
Erasme Hospital Universite Libre de Bruxelles/NL
/
Freeman Hospital/GB
/
Genesis Healthcare/AU
/
Icahn School of Medicine/US
/
Instituto Dante Pazzanese de Cardiologia/BR
/
Medtronic/US
/
Montefiore Medical Center/US
/
Piedmont Heart Institute/GE
/
Columbia University Medical Center+US